Sphere Entertainment Co Ordinary Shares - Class A SPHR 深 滬
已收盤 12-24 16:00:00 美东时间
93.99
+0.070
+0.07%
華盛通- 最 高94.74
- 今 開94.03
- 成交量 91.37万股
- 最 低 92.60
- 昨 收 93.92
- 總市值 33.84亿
- 52周最高 96.73
- 市盈率 靜 --
- 換手率 2.54%
- 52周最低 23.89
- 委 比 -5.00%
- 總股本 3599.94万
- 歷史最高 96.73
- 量 比 1.06
- 振 幅 2.28%
- 歷史最低 6.38
- 每 手 1
- 風險率 16.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
12-22 15:05
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
12-19 10:15
Morgan Stanley Upgrades Sphere Entertainment to Overweight, Raises Price Target to $105
Morgan Stanley analyst Benjamin Swinburne upgrades Sphere Entertainment (NYSE:SPHR) from Equal-Weight to Overweight and raises the price target from $75 to $105.
12-18 19:56
Seaport Global Downgrades Sphere Entertainment to Neutral
Seaport Global analyst David Joyce downgrades Sphere Entertainment (NYSE:SPHR) from Buy to Neutral.
12-16 19:00
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
12-05 08:35
JP Morgan Maintains Overweight on Sphere Entertainment, Raises Price Target to $91
JP Morgan analyst David Karnovsky maintains Sphere Entertainment (NYSE:SPHR) with a Overweight and raises the price target from $80 to $91.
12-05 01:41
Looking Into Sphere Entertainment Co's Recent Short Interest
Sphere Entertainment Co's (NYSE:SPHR) short interest as a percent of float has ...
12-02 02:00
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks
Lucid, Avis, Hims & Hers Health and Upstart are some of the most heavily shorted stocks right now. Here's a look at the top ten.
11-14 04:05
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
Sphere Entertainment Q3 EPS $(2.80) Misses $(1.88) Estimate, Sales $262.511M Miss $264.429M Estimate
Sphere Entertainment (NYSE:SPHR) reported quarterly losses of $(2.80) per share which missed the analyst consensus estimate of $(1.88) by 49.17 percent. This is a 5.08 percent increase over losses of $(2.95) per share
11-04 20:31
